Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts

RituxiCAN-C4 combined an open-labeled randomized controlled trial (RCT) in 7 UK centers to assess whether rituximab could stabilize kidney function in patients with chronic rejection, with an exploratory analysis of how B cell-depletion influenced T cell anti-donor responses relative to outcome. Bet...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Shiu, Kin Yee, Stringer, Dominic, McLaughlin, Laura, Shaw, Olivia, Brookes, Paul, Burton, Hannah, Wilkinson, Hannah, Douthwaite, Harriet, Tsui, Tjir-Li, Mclean, Adam, Hilton, Rachel, Griffin, Sian, Geddes, Colin, Ball, Simon, Baker, Richard, Roufosse, Candice, Horsfield, Catherine, Dorling, Anthony
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7012933/
https://ncbi.nlm.nih.gov/pubmed/32117242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00079
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars